U of T researchers develop new generation CAR T-cells for cancer therapy
With CAR T-cell therapy one of the promising technologies emerging in targeted cancer treatment, University of Toronto scientists have taken a step forward in improving the potential effectiveness of this therapeutic approach.
FACIT Falcons' Fortunes Pitch Competition
FACIT Falcons' Fortunes 2018 - Pitch Competition Concept: Falcons’ Fortunes (based on the popular TV series Dragons’ Den) invites Ontario-based entrepreneurs working in the oncology space to pitch in...
Stem-cell researchers solve mystery of relapse in acute myeloid leukemia
Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins.
Novartis, Bristol-Myers Squibb evaluate potential metastatic colorectal cancer treatments | Biotechnology Focus | Biotechnology Focus – Leading change in Canada’s life science industry, from innovation to business
Colorectal cancer is the third most common type of cancer in men and the second most common in women, with approximately 1.4 million new diagnoses in 2012. For the same period, approximately 694,000 d...
Facit Falcons | OICR Events
Concept: Falcons' Fortunes (based on the popular TV series Dragons' Den) invites Ontario-based entrepreneurs working in the oncology space to pitch innovative research ideas to a panel of friendly investors. Hosted by the FACIT Falcons (i.e. the FACIT team), this annual event will see entrepreneurial researchers vie for the $50,000 Ernsting Entrepreneurship Award to invest in the most promising oncology research idea 1.
Celgene picks up Triphase asset for glioblastoma and multiple myeloma
BioWorld Online is the news service of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep you up to date on all of the industry's business, science and regulatory news -- mergers and collaborations, FDA hearings and results, breakthroughs in research and much more.
Proteocyte Diagnostics launches Straticyte™ to US market at AAOMS Annual Meeting
Last week Proteocyte Diagnostics launched Straticyte at the American Association of Oral Maxillofacial Surgeons 98th Annual Meeting. Straticyte was featured as a new product to over 4000 attendees including 1500 Oral Maxillofacial Surgeons. Proteocyte Diagnostics also presented a poster outlining Straticyte's capability to advance diagnostics for oral precancer and exhibited in the multiday tradeshow.
New partnership brings Toronto researchers together to better understand the molecular origins of breast cancer
Researchers from the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital have enlisted the help of OICR’s Transformative Pathology Program in their ongoing research to identify common biomarkers for breast cancer – and ultimately to better diagnose and target treatment for patients.
Profound Medical Corp. Announces First Patient Treated in TACT Pivotal Clinical Trial at Vanderbilt University Medical Center
TORONTO, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) ("Profound" or the "Company") a medical device company focused on prostate care, today announced that the first patient has been treated in the TACT Pivotal Clinical Trial at Vanderbilt University Medical Center in Nashville, TN.
Elevating Ontario's Innovation Ecosystem - Biotechnology Focus
Strengthening the province’s capacity to commercialize oncology breakthroughs Ontario excels when it comes to the concentration and capabilities of cancer researchers developing novel therapies, diagnostic tools and other technologies. To have an impact on the lives of cancer patients, research needs to be translated out of the lab and into the market. The strength of [&hellip
Rna Diagnostics News - April 2016
Q. You've worked in some very senior roles in the US In Vitro Diagnostics industry. Why did you decide to join Rna Diagnostics, a small Canadian startup? A. Rna Diagnostics provides an opportunity to commercialize a game-changing technology that promises to radically improve the treatment of cancer patients.
Perimeter Medical Imaging Receives FDA Clearance for OTISTM Optical Tissue Imaging System | Business Wire
Perimeter Medical Imaging, Inc., an innovative medical imaging company whose mission is to revolutionize tissue removal surgery for surgeons and patie